Biomaterials, Journal Year: 2024, Volume and Issue: 314, P. 122853 - 122853
Published: Sept. 27, 2024
Language: Английский
Accounts of Chemical Research, Journal Year: 2025, Volume and Issue: unknown
Published: Feb. 4, 2025
ConspectusMicrofluidic technologies have become a highly effective platform for the precise and reproducible production of nanovesicles used in drug nucleic acid delivery. One their key advantages lies one-step assembly multidrug delivery nanovesicles, which improves batch-to-batch reproducibility by minimizing intermediate steps typically required conventional methods. These often involve complex hydrophobic electrostatic interactions, leading to variability nanovesicle composition performance. Microfluidic systems streamline encapsulation diverse therapeutic agents, including hydrophilic acids, proteins, both small molecules, within single chip, ensuring more consistent process. This capability enables codelivery multiple drugs targeting different disease pathways, is particularly valuable reducing risk resistance.Despite promise delivery, clinical translation has been hindered safety concerns, cytotoxicity, overshadowed efforts improve vivo stability efficiency. Positively charged commonly encapsulate negatively tend exhibit significant cytotoxicity. To address this, charge-shifting materials that respond pH changes or surface modifications proposed as promising strategies. Shifting charge from positive neutral negative at physiological can reduce enhancing feasibility these nanovesicle-based therapies.Microfluidic platforms offer control over properties, particle size, rigidity, morphology, Particle size relatively easy adjust controlling flow rates microfluidic channels, with higher generally producing smaller particles. However, continuous tuning rigidity remains challenging. By manipulation interfacial water layer between amphiphilic components during nanoparticle formation, future designs may achieve greater critical improving cellular uptake biodistribution. While shape using chips not yet fully explored biomedical applications, advances science enable this aspect future, offering further customization properties.The integration modification presents challenges due differing speeds processes. Nanovesicle rapid, whereas modifications, such those involving functional biomolecules, occur slowly require purification steps. Recent advances, rotary valve single-axis camshaft mechanisms, mixing stages process, allowing automation modification, thereby reproducibility.In conclusion, represent approach development multifunctional potential precision medicine. obstacles related scalability, remain, innovations chip design, materials, are paving way broader application settings. Future research, potentially incorporating machine learning, could optimize relationship properties biological outcomes, advancing use
Language: Английский
Citations
0
Nano-Micro Letters, Journal Year: 2025, Volume and Issue: 17(1)
Published: Feb. 21, 2025
The emerging messenger RNA (mRNA) nanomedicines have sprung up for disease treatment. Developing targeted mRNA has become a thrilling research hotspot in recent years, as they can be precisely delivered to specific organs or tissues enhance efficiency and avoid side effects. Herein, we give comprehensive review on the latest progress of with targeting functions. its carriers are first described detail. Then, mechanisms passive targeting, endogenous active outlined, focus various biological barriers that may encounter during vivo delivery. Next, emphasis is placed summarizing mRNA-based organ-targeting strategies. Lastly, advantages challenges clinical translation mentioned. This expected inspire researchers this field drive further development technology.
Language: Английский
Citations
0
International Journal of Nanomedicine, Journal Year: 2025, Volume and Issue: Volume 20, P. 3339 - 3361
Published: March 1, 2025
Cancer treatment is continually advancing, with immunotherapy gaining prominence as a standard modality that has markedly improved the management of various malignancies. Despite these advancements, efficacy remains variable, certain cancers exhibiting limited response and patient outcomes differing considerably. Thus, enhancing effectiveness imperative. A promising avenue mRNA delivery, employing carriers such liposomes, peptide nanoparticles, inorganic exosomes to introduce cargos encoding tumor antigens, immune-stimulatory, or immune-modulatory molecules into immune microenvironment (TIME). This method aims activate system target eradicate cells. In this review, we characteristics limitations summarize application mechanisms currently prevalent in mRNA-based treatment. Additionally, given significant clinical checkpoint inhibitors (ICIs) chimeric antigen receptor (CAR)-based cell therapies solid tumors (including melanoma, non-small-cell lung cancer, head neck squamous carcinoma, triple-negative breast gastric cancer) leukemia, which have become first-line treatments, highlight discuss recent progress combining delivery ICIs, CAR-T, CAR-NK, CAR-macrophage therapies. combination enhances targeting capabilities ICIs CAR-cell-based therapies, while also mitigating long-term off-target toxicities associated conventional methods. Finally, analyze current systems, nuclease-induced instability, immunogenicity risks, complex carrier production, knowledge gaps concerning dosing safety. Addressing challenges crucial for unlocking potential cancer immunotherapy. Overall, exploring enriches our comprehension holds promise developing personalized effective strategies, potentially responses patients extending their survival time.
Language: Английский
Citations
0
Nano Letters, Journal Year: 2024, Volume and Issue: 24(28), P. 8609 - 8618
Published: July 2, 2024
Although biomacromolecules are promising cytosolic drugs which have attracted tremendous attention, the major obstacles were cellular membrane hindering entrance and endosome entrapment inducing biomacromolecule degradation. How to avoid those limitations realize directly delivery was still a challenge. Here, we prepared oligoarginine modified lipid assemble nanovesicle for delivery, including mRNA (mRNA) proteins could be delivered into cytoplasm of dendritic cells through subendocytosis-mediated fusion. We named this fusion as MF-LNV. The loaded MF-LNV nanovaccines showed efficient antigen expression elicit robust immuno responses cancer therapy. What's more, protein elicits much stronger CD8
Language: Английский
Citations
3
Nano Letters, Journal Year: 2024, Volume and Issue: unknown
Published: Oct. 7, 2024
The success of mRNA COVID-19 vaccines has reinvigorated research and interest in mRNA-based cancer vaccines. Despite promising results clinical trials, therapeutic have not yet been approved for human use. These are designed to trigger tumor regression, establish enduring antitumor memory, mitigate adverse reactions. However, challenges such as tumor-induced immunosuppression immunoresistance significantly hinder their application. Here, we provide an overview the recent advances neoantigen discovery delivery systems vaccines, focusing on improving efficacy. Additionally, summarize involving discuss prospective strategies overcoming immuneresistance.
Language: Английский
Citations
3
European Journal of Pharmaceutics and Biopharmaceutics, Journal Year: 2024, Volume and Issue: 197, P. 114234 - 114234
Published: Feb. 23, 2024
Language: Английский
Citations
2
Fundamental Research, Journal Year: 2024, Volume and Issue: unknown
Published: Nov. 1, 2024
Language: Английский
Citations
2
Journal of Controlled Release, Journal Year: 2024, Volume and Issue: 377, P. 413 - 426
Published: Nov. 26, 2024
Language: Английский
Citations
2
Journal of Drug Delivery Science and Technology, Journal Year: 2024, Volume and Issue: 95, P. 105547 - 105547
Published: March 14, 2024
Language: Английский
Citations
1
Drug Delivery and Translational Research, Journal Year: 2024, Volume and Issue: 14(10), P. 2823 - 2844
Published: June 3, 2024
Abstract Breast cancer (BC) prevails as a major burden on global healthcare, being the most prevalent form of among women. BC is complex and heterogeneous disease, current therapies, such chemotherapy radiotherapy, frequently fall short in providing effective solutions. These treatments fail to mitigate risk recurrence cause severe side effects that, turn, compromise therapeutic responses patients. Over last decade, several strategies have been proposed overcome these limitations. Among them, RNA-based technologies demonstrated their potential across various clinical applications, notably therapy. However, RNA therapies are still limited by series critical issues like off-target effect poor stability circulation. Thus, novel approaches investigated improve targeting bioavailability formulations achieve an appropriate outcome. Lipid nanoparticles (LNPs) largely proven be advantageous carrier for nucleic acids RNA. This perspective explores recent advances technology with emphasis LNPs’ utilization nanocarriers therapy progresses applications. Graphical
Language: Английский
Citations
1